When is ethics approval unethical?

Bioethics is an area of deep personal interest to me, and it is something that has challenged me many times in my entrepreneurial career. There are always opportunities to cut corners, to be “selective” with information, to be biased in decision making. Biomedical research and product development is tough because the dollars at stake are…

The Cancer Stem Cell Hypothesis

When I first read that HC Wainwright had initiated coverage on Novogen (ASX : NRT) today, I was pretty much prepared to go in guns blazing on yet another paid-for and underwhelming analyst report. I was even going to ask the basic question that every self-styled ASX biotech pundit should ask, and that is “what cereal…

Novogen : Unacceptable Behaviour (Part II)

In this continuation of my prior rant about Novogen CEO Graham Kelly’s questionable interactions with shareholders on HotCopper, I want to specifically review each of the “questions” that appeared on HotCopper and perhaps share some perspectives that will help you to understand why I really despise this kind of informal chit-chat. I note that I have…

Cynata Therapeutics : The Flip Flop

I make no effort to hide the fact that Cynata (ASX : CYP) is one of the ASX-listed biotechnology companies that I despise the most. It is the worst example of a “hollow chocolate bunny” that will only ever deliver on wild speculation from retail punters wowed by the words “stem cells.” If, one day,…

Orthocell : Love Me Tendon, Love Me True…

In a previous post, I discussed the potential risk to the “quackery” end of Australia’s stem cell medicine industry if the TGA ever had a change of heart about how autologous (“from self”) cell therapies are regulated. At one end of the spectrum we have proven cell therapies that have been saving lives for a long…

Aussie stem cell clinics beware : the TGA cometh

Back in January, the Therapeutic Goods Administration (TGA) announced a public consultation on the matter of the clinical use and regulation of autologous stem cell transplants. I did not submit a response, but I wish I had. Fortunately many people far smarter and informed than I, did, and I am very keen to see what the outcome…

Cynata : The Saga Continues

It was actually some activity involving my personal blog that, in some ways, led to the creation of  “The Long Tail”. A week ago I posted a brief commentary (rant?) on Cynata Limited (ASX:CYP), as an example of an underwhelming microcap ASX-listed biotechnology company. I will not repeat the comments I wrote here but you can read the original posting.…